Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
In this video, Jorge E. Cortes, MD, of the University of Texas MD Anderson Cancer Center in Houston, discusses results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
Cortes presented the results of the study (abstract 7002) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
